
Opinion|Videos|March 13, 2025
How would therapeutic options change if this patient was asymptomatic?
Author(s)Abhishek Tripathi, MD
An expert discusses alternative treatment options for a symptomatic patient with metastatic castration-resistant prostate cancer (mCRPC) and highlights the caveats around the data from the Phase 3 ALSYMPCA study of radium-223, including its conduct in an era prior to the introduction of abiraterone (ABI) and enzalutamide (ENZA).
Advertisement
Episodes in this series

- What if this patient was symptomatic? What other options might you consider?
- What are the caveats around data from the phase 3 ALSYMPCA study of Ra-223 for metastatic castration-resistant prostate cancer (mCRPC)? (eg, conducted in era before introduction of ABI and ENZA)
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
2
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
3
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5


















